ELEV Stock Overview
An oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Elevation Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.64 |
| 52 Week High | US$5.83 |
| 52 Week Low | US$0.44 |
| Beta | 1.25 |
| 11 Month Change | 6.00% |
| 3 Month Change | -18.25% |
| 1 Year Change | 24.71% |
| 33 Year Change | -89.54% |
| 5 Year Change | n/a |
| Change since IPO | -94.44% |
Recent News & Updates
Recent updates
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
May 03Elevation Oncology: Rising On News, But Not The Time To Buy
Jan 17Elevation Oncology GAAP EPS of -$0.86 misses by $0.07
Aug 04Elevation Oncology secured $50M loan facility with K2 HealthVentures
Jul 28We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely
May 10
We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate
Jan 25Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth
Sep 25Shareholder Returns
| ELEV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.4% | 2.5% | 1.0% |
| 1Y | 24.7% | 15.6% | 31.4% |
Return vs Industry: ELEV exceeded the US Biotechs industry which returned 15.6% over the past year.
Return vs Market: ELEV underperformed the US Market which returned 30.7% over the past year.
Price Volatility
| ELEV volatility | |
|---|---|
| ELEV Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ELEV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ELEV's weekly volatility has decreased from 23% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 29 | Joe Ferra | elevationoncology.com |
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company’s lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2.
Elevation Oncology, Inc. Fundamentals Summary
| ELEV fundamental statistics | |
|---|---|
| Market cap | US$37.60m |
| Earnings (TTM) | -US$41.95m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs ELEV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELEV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$41.95m |
| Earnings | -US$41.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 44.7% |
How did ELEV perform over the long term?
See historical performance and comparison